Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 4
2002 3
2003 10
2004 11
2005 8
2006 10
2007 21
2008 23
2009 12
2010 25
2011 22
2012 29
2013 34
2014 24
2015 29
2016 23
2017 23
2018 26
2019 29
2020 27
2021 25
2022 17
Text availability
Article attribute
Article type
Publication date

Search Results

384 results
Results by year
Filters applied: . Clear all
Page 1
Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a "Hammer" and "Anvil".
Melzer MK, Lopez-Martinez A, Altomonte J. Melzer MK, et al. Biomedicines. 2017 Feb 10;5(1):8. doi: 10.3390/biomedicines5010008. Biomedicines. 2017. PMID: 28536351 Free PMC article. Review.
Vesicular stomatitis virus (VSV), a negative-strand RNA virus, is under intense development as an oncolytic virus due to a variety of favorable properties, including its rapid replication kinetics, inherent tumor specificity, and its pote
Vesicular stomatitis virus (VSV), a negative-strand RNA virus, is under intense development as an oncolytic
Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice.
Evgin L, Kottke T, Tonne J, Thompson J, Huff AL, van Vloten J, Moore M, Michael J, Driscoll C, Pulido J, Swanson E, Kennedy R, Coffey M, Loghmani H, Sanchez-Perez L, Olivier G, Harrington K, Pandha H, Melcher A, Diaz RM, Vile RG. Evgin L, et al. Sci Transl Med. 2022 Apr 13;14(640):eabn2231. doi: 10.1126/scitranslmed.abn2231. Epub 2022 Apr 13. Sci Transl Med. 2022. PMID: 35417192 Free PMC article.
Oncolytic viruses (OVs) encoding a variety of transgenes have been evaluated as therapeutic tools to increase the efficacy of chimeric antigen receptor (CAR)-modified T cells in the solid tumor microenvironment (TME). ...In vivo expansion of dual-specific (DS) CAR T cells
Oncolytic viruses (OVs) encoding a variety of transgenes have been evaluated as therapeutic tools to increase the efficacy of chimeri
Expanding the Spectrum of Pancreatic Cancers Responsive to Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Challenges and Solutions.
Holbrook MC, Goad DW, Grdzelishvili VZ. Holbrook MC, et al. Cancers (Basel). 2021 Mar 9;13(5):1171. doi: 10.3390/cancers13051171. Cancers (Basel). 2021. PMID: 33803211 Free PMC article. Review.
Pancreatic ductal adenocarcinoma (PDAC) is a devastating malignancy with poor prognosis and a dismal survival rate, expected to become the second leading cause of cancer-related deaths in the United States. Oncolytic virus (OV) is an anticancer approach that utilize …
Pancreatic ductal adenocarcinoma (PDAC) is a devastating malignancy with poor prognosis and a dismal survival rate, expected to become the s …
Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy.
Simovic B, Walsh SR, Wan Y. Simovic B, et al. Oncolytic Virother. 2015 Oct 15;4:157-67. doi: 10.2147/OV.S66079. eCollection 2015. Oncolytic Virother. 2015. PMID: 27512679 Free PMC article. Review.
Vesicular stomatitis virus is a prominent oncolytic virus with several features that promise synergy between oncolytic virotherapy and immunotherapy. This review will address the cytotoxicity of vesicular stomatitis virus
Vesicular stomatitis virus is a prominent oncolytic virus with several features that promise synergy betw
Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.
Seegers SL, Frasier C, Greene S, Nesmelova IV, Grdzelishvili VZ. Seegers SL, et al. J Virol. 2020 Jan 17;94(3):e01643-19. doi: 10.1128/JVI.01643-19. Print 2020 Jan 17. J Virol. 2020. PMID: 31694943 Free PMC article.
Vesicular stomatitis virus (VSV) based oncolytic viruses are promising agents against various cancers. ...Additional experiments indicated that the acquired G mutations improved VSV replication, at least in part due to improved virus attachment
Vesicular stomatitis virus (VSV) based oncolytic viruses are promising agents against various cancers. ...Additi
Diversity in responses to oncolytic Lassa-vesicular stomatitis virus in patient-derived glioblastoma cells.
Kim TE, Puckett S, Zhang K, Herpai DM, Ornelles DA, Davis JN, van den Pol AN, Debinski W, Lyles DS. Kim TE, et al. Mol Ther Oncolytics. 2021 Jun 12;22:232-244. doi: 10.1016/j.omto.2021.06.003. eCollection 2021 Sep 24. Mol Ther Oncolytics. 2021. PMID: 34514102 Free PMC article.
The difficulty of glioblastoma treatment makes it a good candidate for novel therapies, such as oncolytic viruses. Vesicular stomatitis virus expressing Lassa virus glycoprotein (Lassa-VSV) showed significant promise in animal models using estab …
The difficulty of glioblastoma treatment makes it a good candidate for novel therapies, such as oncolytic viruses. Vesicular
Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer.
Hastie E, Grdzelishvili VZ. Hastie E, et al. J Gen Virol. 2012 Dec;93(Pt 12):2529-2545. doi: 10.1099/vir.0.046672-0. Epub 2012 Oct 10. J Gen Virol. 2012. PMID: 23052398 Free PMC article. Review.
Oncolytic virus (OV) therapy is an emerging anti-cancer approach that utilizes viruses to preferentially infect and kill cancer cells, while not harming healthy cells. Vesicular stomatitis virus (VSV) is a prototypic non-segmented, negative-stra
Oncolytic virus (OV) therapy is an emerging anti-cancer approach that utilizes viruses to preferentially infect and kill cance
Mechanisms that allow vaccination against an oncolytic vesicular stomatitis virus-encoded transgene to enhance safety without abrogating oncolysis.
AuYeung AWK, Mould RC, Stegelmeier AA, van Vloten JP, Karimi K, Woods JP, Petrik JJ, Wood GA, Bridle BW. AuYeung AWK, et al. Sci Rep. 2021 Jul 27;11(1):15290. doi: 10.1038/s41598-021-94483-z. Sci Rep. 2021. PMID: 34315959 Free PMC article.
Vaccination can prevent viral infections via virus-specific T cells, among other mechanisms. A goal of oncolytic virotherapy is replication of oncolytic viruses (OVs) in tumors, so pre-existing T cell immunity against an OV-encoded transgene would seem counte …
Vaccination can prevent viral infections via virus-specific T cells, among other mechanisms. A goal of oncolytic virotherapy i …
Vesicular stomatitis virus as an oncolytic vector.
Barber GN. Barber GN. Viral Immunol. 2004;17(4):516-27. doi: 10.1089/vim.2004.17.516. Viral Immunol. 2004. PMID: 15671748 Review.
Recent data has shown that viruses such as vesicular stomatitis virus (VSV), a relatively non-pathogenic, negative-stranded RNA virus, can preferentially replicate in malignant cells and less so in normal cells. VSV appears able to carry out this funct …
Recent data has shown that viruses such as vesicular stomatitis virus (VSV), a relatively non-pathogenic, negative-stra …
384 results